<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ropivacaine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ropivacaine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ropivacaine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9873" href="/d/html/9873.html" rel="external">see "Ropivacaine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11999" href="/d/html/11999.html" rel="external">see "Ropivacaine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F219215"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Naropin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868194"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Naropin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061901"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Local Anesthetic, Injectable</span></li></ul></div>
<div class="block don drugH1Div" id="F53462580"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>: Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient; should only be administered under the supervision of a qualified physician experienced in the use of anesthetics. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20216035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20216035'])">Ref</a></span>). Dosing units are variable (mL/kg, <b>mg/kg</b>); use extra precaution to ensure accuracy and minimize potential toxicity.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0df79c5-b9d4-4b65-ac2c-a37c1a38f13e">Central nerve blocks/anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nerve blocks/anesthesia (eg, caudal, lumbar, thoracic):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caudal block:</i> Term neonate: Caudal injection: 0.2% (2 mg/mL) solution: 1 mL/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18345720','lexi-content-ref-Wulf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18345720','lexi-content-ref-Wulf.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epidural block (eg, lumbar, thoracic):</i> Term neonate: Epidural injection: 0.2% (2 mg/mL) solution: Reported range: 0.5 to 1 mL/kg; if repeat injections necessary, a decreased dose is necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to ½ of the initial. If additional doses are necessary, doses should be reduced to ½ of the previous dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16101704','lexi-content-ref-18345720','lexi-content-ref-1340763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16101704','lexi-content-ref-18345720','lexi-content-ref-1340763'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epidural, continuous infusion:</i> Term neonate: Epidural injection: Bolus: Usual concentration: 0.2% (2 mg/mL) solution: Usual range: 0.5 to 1 mL/kg, bolus dose volume dependent upon site (eg, thoracic [lower dose range], lumbar); reported range: 0.45 to 1 mL/kg. In some cases, a more dilute solution (eg, 0.1% [1 mg/mL]) may be required to ensure adequate volume and minimize toxicity. Follow with continuous epidural infusion of 0.2% (2 mg/mL) solution at 0.2 <b>mg/kg</b>/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16101704','lexi-content-ref-18345720','lexi-content-ref-25693139','lexi-content-ref-1340763','lexi-content-ref-22798528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16101704','lexi-content-ref-18345720','lexi-content-ref-25693139','lexi-content-ref-1340763','lexi-content-ref-22798528'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812549"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>: Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20216035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20216035'])">Ref</a></span>). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics. Dosing units are variable (mL/kg, <b>mg/kg</b>); use extra precaution to ensure accuracy and minimize potential toxicity.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0df79c5-b9d4-4b65-ac2c-a37c1a38f13e">Central nerve blocks/anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nerve blocks/anesthesia (eg, caudal, lumbar, thoracic): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caudal block:</i> Infants and Children: Caudal injection: 0.2% (2 mg/mL) solution: 0.5 to 1 mL/kg; some experts suggest a maximum volume of 25 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9813532','lexi-content-ref-3605712','lexi-content-ref-25693139','lexi-content-ref-12753447','lexi-content-ref-Lonnqvist.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9813532','lexi-content-ref-3605712','lexi-content-ref-25693139','lexi-content-ref-12753447','lexi-content-ref-Lonnqvist.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epidural block</i>
<i>(eg, lumbar, thoracic):</i> Infants, Children, and Adolescents: Epidural injection 0.2% (2 mg/mL): 0.7 mL/kg. <b>Note:</b> For infants (particularly young infants) if repeat injections necessary, a decreased dose may be necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to ½ of the initial. If additional doses are necessary, doses should be reduced to ½ of the previous dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10349927','lexi-content-ref-1340763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10349927','lexi-content-ref-1340763'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epidural, continuous infusion</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;3 months: Epidural injection: Bolus: Usual concentration 0.2% (2 mg/mL) solution: Reported range: 0.5 to 1 mL/kg. In some cases, a more dilute solution (eg, 0.1% [1 mg/mL]) may be required to ensure adequate volume and minimize toxicity. Follow with continuous epidural infusion of 0.2% (2 mg/mL) solution at 0.2 <b>mg/kg</b>/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16101704','lexi-content-ref-Hansen.1','lexi-content-ref-1340763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16101704','lexi-content-ref-Hansen.1','lexi-content-ref-1340763'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months, Children, and Adolescents: Epidural injection: 0.2% (2 mg/mL) solution: Bolus: Reported range: 0.5 to 1 mL/kg administered over several minutes (eg, 3 to 5 minutes) followed by continuous epidural infusion at 0.2 to 0.5 <b>mg/kg/</b>hour; in trials, 0.4 <b>mg/kg</b>/hour was frequently reported; some suggest a maximum infusion rate of 0.2 <b>mg/kg/</b>hour for infants &lt;6 months of age although higher rates have been reported; in adults, usual rates are 6 to 14 mL/hour of 0.2% solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18205962','lexi-content-ref-16101704','lexi-content-ref-Cote.2','lexi-content-ref-Hansen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18205962','lexi-content-ref-16101704','lexi-content-ref-Cote.2','lexi-content-ref-Hansen.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="10395f46-81ec-4bb4-86f9-55a329df9fa5">Peripheral nerve blocks/local anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral nerve blocks/local anesthesia:</b> Limited data available: <b>Note: </b>Dose varies with location of block (ie, procedure), depth of anesthesia, vascularity of tissues, duration of anesthesia, and patient parameters (eg, age, weight, condition).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single injection:</i> The volume of dose (mL/kg) and concentration of solution are site-specific based upon anatomy and variable among patients and procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2','lexi-content-ref-1340763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2','lexi-content-ref-1340763'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents: Suggested or reported dose volumes presented; not to exceed a suggested maximum dose of 3 <b>mg/kg</b>/dose based on lean body mass; dosing based on extrapolation from adult experience; additional data necessary to more clearly define the pediatric upper dose limit. <b>Note:</b> For infants &lt;6 months of age, dose reductions (eg, by 30%) have been suggested by experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2','lexi-content-ref-26308515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2','lexi-content-ref-26308515'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Commonly accepted doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">Head and neck blocks: 0.05 mL/kg.</p>
<p style="text-indent:-2em;margin-left:12em;">Maxillary nerve: 0.15 mL/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24525630','lexi-content-ref-22587691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24525630','lexi-content-ref-22587691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Upper extremity blocks:</p>
<p style="text-indent:-2em;margin-left:12em;">Brachial plexus: 0.2 to 0.3 mL/kg.</p>
<p style="text-indent:-2em;margin-left:12em;">Digital nerve: ≤0.2% (2 mg/mL) solution: 0.05 mL/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Truncal blocks:</p>
<p style="text-indent:-2em;margin-left:12em;">Transversus abdominis plane: 0.2 to 0.5 mL/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25693139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25693139'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Ilioinguinal nerve: 0.075 mL/kg.</p>
<p style="text-indent:-2em;margin-left:12em;">Rectus sheath: 0.1 to 0.2 mL/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Lower extremity blocks:</p>
<p style="text-indent:-2em;margin-left:12em;">Femoral nerve: 0.2% to 0.5% (2 to 5 mg/mL) solution: 0.2 to 0.4 mL/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2','lexi-content-ref-24172670','lexi-content-ref-27920573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2','lexi-content-ref-24172670','lexi-content-ref-27920573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Sciatic nerve: 0.2 to 0.3 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous peripheral nerve block infusion (CPNB):</i> Dosing based on trial experience (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19697092','lexi-content-ref-16787931','lexi-content-ref-26786058','lexi-content-ref-25176318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19697092','lexi-content-ref-16787931','lexi-content-ref-26786058','lexi-content-ref-25176318'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial bolus: 0.2% (2 mg/mL) solution: Dose dependent on nerve catheter location: Commonly reported dose range: ~0.5 to 1.32 <b>mg/kg</b>; some patients and/or catheter/nerve sites may require a higher bolus dose; a trial evaluating 403 pediatric catheter placements reported an overall median bolus for all catheter sites of 1.32 <b>mg/kg</b> (interquartile range [IQR]: 0.82 to 1.95 <b>mg/kg</b>); another trial reporting on 339 pediatric catheter placements reported a mean initial bolus dose of 0.49 to 0.98 <b>mg/kg</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous peripheral nerve block infusion: 0.2% (2 mg/mL) solution: Reported mean rate range: 0.11 to 0.25 <b>mg/kg</b>/hour (most experience reported at 0.2 to 0.25 <b>mg/kg</b>/hour); reported IQR range from 403 pediatric catheter placements: 0.12 to 0.33 <b>mg/kg/</b>hour (depending upon catheter site) with a usual duration &lt;72 hours; the majority of experience is postoperative pain management following orthopedic procedures including administration via On-Q pump or Ambu Smart-Infuser.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95214460-3eae-4f3d-8c84-52eba66add14">Spinal anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal anesthesia: </b>Limited data available: Infant, Children, and Adolescents ≤17 years: Intrathecal (via LP site; L 3-5): Preservative-free 0.5% (5 mg/mL) isobaric solution: 0.5 <b>mg/kg</b>; maximum dose: 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15616053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15616053'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729820"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, ropivacaine and its metabolites are renally excreted, and the risk of toxic reactions may be greater.</p></div>
<div class="block dohp drugH1Div" id="F52729821"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; ropivacaine undergoes hepatic metabolism and patients may be at a greater risk for developing toxic drug levels.</p></div>
<div class="block doa drugH1Div" id="F219219"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9873" href="/d/html/9873.html" rel="external">see "Ropivacaine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">Dose varies with procedure, onset and depth of anesthesia desired, vascularity of tissues, duration of anesthesia, and condition of patient. A test dose (eg, 3 to 5 mL) of short-acting local anesthetic containing epinephrine should be administered prior to epidural anesthesia or induction of complete block with ropivacaine. Incremental ropivacaine dosing is recommended. Adults:</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="013a59a6-59f6-46ae-a85d-0d3afe29184e">Surgical anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Lumbar epidural block for surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 30 <b>mL</b> of 0.5% solution</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 25 <b>mL</b> of 0.75% solution</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 20 <b>mL</b> of 1% solution</p>
<p style="text-indent:-2em;margin-left:4em;">Lumbar epidural block for cesarean delivery:</p>
<p style="text-indent:-2em;margin-left:6em;">20 to 30 <b>mL</b> dose of 0.5% solution</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 20 <b>mL</b> dose of 0.75% solution</p>
<p style="text-indent:-2em;margin-left:4em;">Thoracic epidural block:</p>
<p style="text-indent:-2em;margin-left:6em;">5 to 15 <b>mL</b> dose of 0.5% solution</p>
<p style="text-indent:-2em;margin-left:6em;">5 to 15 <b>mL</b> dose of 0.75% solution</p>
<p style="text-indent:-2em;margin-left:4em;">Major nerve block:</p>
<p style="text-indent:-2em;margin-left:6em;">35 to 50 <b>mL</b> dose of 0.5% solution</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 40 <b>mL</b> dose of 0.75% solution</p>
<p style="text-indent:-2em;margin-left:4em;">Field block: 1 to 40 <b>mL</b> dose of 0.5% solution</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="baffbfea-4a11-4d2f-8cd5-24f9011c2294">Labor pain management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Labor pain management:</b> Lumbar epidural: Initial: 10 to 20 <b>mL</b> 0.2% solution; continuous infusion dose: 6 to 14 <b>mL</b>/hour of 0.2% solution with intermittent bolus injections of up to 10 to 15 <b>mL</b>/hour of 0.2% solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="609599cf-b2b9-45e6-aa2b-714fb4bb82c5">Postoperative pain management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative pain management: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Peripheral nerve block: Continuous infusion dose: 5 to 10 <b>mL</b>/hour of 0.2% solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18155052','lexi-content-ref-11094003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18155052','lexi-content-ref-11094003'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Lumbar or thoracic epidural: Continuous infusion dose: 6 to 14 <b>mL</b>/hour of 0.2% solution</p>
<p style="text-indent:-2em;margin-left:4em;">Infiltration/minor nerve block:</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 100 <b>mL</b> dose of 0.2% solution</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 40 <b>mL</b> dose of 0.5% solution</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991474"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, ropivacaine and its metabolites are renally excreted, and the risk of toxic reactions may be greater.</p></div>
<div class="block doha drugH1Div" id="F50988816"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution; ropivacaine undergoes hepatic metabolism and patients may be at a greater risk for developing toxic drug levels.</p></div>
<div class="block adr drugH1Div" id="F219192"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (6% to 20%), hypotension (32% to 69%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (13% to 25%), vomiting (7% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (4% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1% to 5%), hypertension (1% to 5%), tachycardia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Disorder of breast milk secretion (1%), oliguria (1% to 5%), poor progression of labor (1%), urinary retention (1% to 5%), urinary tract infection (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (1%), chills (≤3%), dizziness (3%), headache (5% to 8%), hypoesthesia (2%), pain (4% to 8%), paresthesia (2% to 6%), rigors (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1% to 5%), rhinitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, cardiac arrhythmia, deep vein thrombosis, ECG abnormality, extrasystoles, orthostatic hypotension, phlebitis, pulmonary embolism, ST segment changes on ECG, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Fecal incontinence, tenesmus</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence, urination disorder, uterine atony</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, amnesia, asthenia, coma, confusion, drowsiness, emotional lability, hallucination, Horner syndrome, hypothermia, hypotonia, insomnia, malaise, nervousness, neuropathy, nightmares, paresis, seizure, stupor, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia, hypokinesia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, cough</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury</p></div>
<div class="block coi drugH1Div" id="F219203"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ropivacaine, amide-type local anesthetics (eg, bupivacaine, mepivacaine, lidocaine), or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Intravenous regional anesthesia (Bier block); obstetric paracervical block anesthesia</p></div>
<div class="block war drugH1Div" id="F219189"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypotension, hypovolemia, heart block, or cardiovascular disease; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurological disorders: Use with caution in patients with neurological disorders; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with acute porphyria; consider use of alternative agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disorders: Use with caution in patients with psychiatric disorders; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patient; may be at greater risk for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly: may be at greater risk for toxicity. Cardiovascular adverse events (bradycardia, hypotension) may be age-related (more common in patients &gt;61 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F219198"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naropin: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (20 mL, 30 mL, 200 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (20 mL, 30 mL, 100 mL, 200 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p></div>
<div class="block geq drugH1Div" id="F219185"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323799"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Naropin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $0.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $0.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/mL (per mL): $1.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $1.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ROPivacaine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $0.30 - $0.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $0.16 - $1.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/mL (per mL): $1.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.60 - $1.98</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868195"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naropin: 2 mg/mL (100 mL, 200 mL); 5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (10 mL); 10 mg/mL (10 mL, 20 mL)</p></div>
<div class="block admp drugH1Div" id="F52613830"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administered via local infiltration, epidural block and epidural infusion, or intermittent bolus; if further dilution necessary, ensure appropriate diluent (eg, preservative-free). Prior to ropivacaine administration as epidural anesthesia or induction of complete block, a test dose of short acting local anesthetic with epinephrine should be administered to verify avoidance of intravascular site. Incremental ropivacaine dosing is recommended. Do not administer large volume of anesthetic rapidly. Various infusion pumps are on market and used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to nerves for pre- or postoperative regional anesthesia; in most pediatric trials, an On-Q pump was used. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (see https://www.ismp.org/Newsletters/acutecare/archives/May09.asp).</p></div>
<div class="block adm drugH1Div" id="F219200"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administered via local infiltration, epidural block and epidural infusion, or intermittent bolus. Avoid rapid administration of large volumes of ropivacaine; use fractional (incremental) doses with the lowest effective dose and concentration required to produce the desired result. Prior to epidural anesthesia or induction of complete block, a test dose (eg, 3 to 5 mL) of short-acting local anesthetic with epinephrine should be administered. The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to nerves for pre- or postoperative regional anesthesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F219212"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C between 30°C (59°F to 86°F). Infusions should be discarded after 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53568744"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Production of local or regional anesthesia for surgery administered as an epidural block, including cesarean section, major nerve block, or local infiltration; acute pain management administered as an epidural continuous infusion, intermittent bolus (eg, postoperative, labor), or local infiltration (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F219253"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ROPivacaine may be confused with BUPivacaine, rOPINIRole</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">Infusion bottles of Naropin (ropivacaine) and Ofirmev (acetaminophen) look similar. Potentially fatal mix-ups have been reported in which a glass bottle of Naropin was mistaken for Ofirmev in perioperative areas.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F219240"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F219194"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of ROPivacaine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of ROPivacaine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F219205"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ropivacaine crosses the placenta following epidural administration (Matsota 2009; Simpson 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Ropivacaine may potentially cause varying degrees of maternal, fetal, and neonatal toxicity involving the CNS, peripheral vascular tone, and cardiac function depending on dose and administration technique.</p>
<p style="text-indent:0em;margin-top:2em;">Ropivacaine is approved for use in obstetric analgesia/anesthesia (ACOG 2019; Reschke 2020).</p></div>
<div class="block mopp drugH1Div" id="F53568743"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">After epidural or subarachnoid administration: Blood pressure, heart rate, respiration, signs of CNS toxicity (eg, lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia).</p></div>
<div class="block pha drugH1Div" id="F219188"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>
<div class="block phk drugH1Div" id="F219202"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Anesthesia (route dependent): 3 to 15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration (dose and route dependent): 3 to 15 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94%, primarily to alpha1-acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:2em;">Children: Epidural infusion: 2.1 to 4.2 L/kg (Hansen 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Adults: Intravascular infusion: 41 ± 7 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, via CYP1A2 to metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Epidural: Terminal phase: 4.9 hours (range: 3 to 6.7 hours) (Hansen 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Epidural: 5 to 7 hours; IV: Terminal: 111 ± 62 minutes (Lee, 1989)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Dose and route dependent: Caudal:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Median: 60 minutes (range: 15 to 90 minutes) (Wulf 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Mean: 60 minutes (range: 12 to 249 minutes (Lonnqvist 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (86%; 1% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F219206"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropinaest | Ropivacain Actavis | Ropivacain Chiesi | Ropivacain sintetica</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropibam | Ropivacaine aft | Ropivacaine kabi | Ropivacaine Sandoz</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacain Sandoz | Ropivacaine Fresenius Kabi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropi | Ropi bolsa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ropivacain sintetica</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ropivacaine hydrochloride and sodium chloride</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacain Actavis | Ropivacain altan | Ropivacain bioq | Ropivacain cipla | Ropivacain deltamedica | Ropivacain hcl noridem | Ropivacain Hexal | Ropivacain sintetica | Ropivacainhydrochlorid GRY</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacaine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Naropin polybag | Ropivacaina g.e.s | Ropivacaina inibsa | Ropivacaina Kabi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Naropeine | Ropivacaine altan | Ropivacaine b.braun | Ropivacaine kabi | Ropivacaine Mylan | Ropivacaine noridem | Ropivacaine teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacaine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Naropeine | Ropivacaine/kabi | Ropivacaine/teva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Naropina | Ropivacaina | Ropivacaina cloridrato altan pharma | Ropivacaina cloridrato s.a.l.f. | Ropivacaina galenica senese | Ropivacaina molteni | Ropivacaina Sandoz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anapeine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacain sintetica</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacaine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropibam | Ropivacaine kabi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ropivacaine bioq</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivacaine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Naropeine | Ropivacaina | Ropivacaina actavis</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropivabin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Narop | Ropivacain fresenius kabi | Ropivakain Actavis</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ropivacaine Infomed | Ropivacaine kabi</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Naropin | Ropilong</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Naropin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco ropivacaine | Naropin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18155052">
<a name="18155052"></a>Bagry H, de la Cuadra Fontaine JC, Asenjo JF, et al. Effect of a continuous peripheral nerve block on the inflammatory response in knee arthroplasty. <i>Reg Anesth Pain Med.</i> 2008;33(1):17-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/18155052/pubmed" id="18155052" target="_blank">18155052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18205962">
<a name="18205962"></a>Berde CB, Yaster M, Meretoja O, et al. Stable plasma concentrations of unbound ropivacaine during postoperative epidural infusion for 24-72 hours in children. <i>Eur J Anaesthesiol</i>. 2008;25(5):410-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/18205962/pubmed" id="18205962" target="_blank">18205962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16101704">
<a name="16101704"></a>Bösenberg AT, Thomas J, Cronje L, et al. Pharmacokinetics and efficacy of ropivacaine for continuous epidural infusion in neonates and infants. <i>Paediatr Anaesth</i>. 2005;15(9):739-749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/16101704/pubmed" id="16101704" target="_blank">16101704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24525630">
<a name="24525630"></a>Chiono J, Raux O, Bringuier S, et al. Bilateral suprazygomatic maxillary nerve block for cleft palate repair in children: a prospective, randomized, double-blind study versus placebo. <i>Anesthesiology</i>. 2014;120(6):1362-1369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/24525630/pubmed" id="24525630" target="_blank">24525630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.1">
<a name="Cote.1"></a>Coté CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Philadelphia, PA: Elsevier Inc; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.2">
<a name="Cote.2"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19697092">
<a name="19697092"></a>Dadure C, Bringuier S, Raux O, et al. Continuous peripheral nerve blocks for postoperative analgesia in children: feasibility and side effects in a cohort study of 339 catheters. <i>Can J Anaesth</i>. 2009;56(11):843-850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/19697092/pubmed" id="19697092" target="_blank">19697092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16787931">
<a name="16787931"></a>Duflo F, Sautou-Miranda V, Pouyau A, et al. Efficacy and plasma levels of ropivacaine for children: controlled regional analgesia following lower limb surgery. <i>Br J Anaesth</i>. 2006;97(2):250-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/16787931/pubmed" id="16787931" target="_blank">16787931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hansen.1">
<a name="Hansen.1"></a>Hansen TG, Ilett KF, Lim SI, et al. Pharmacokinetics and clinical efficacy of long-term epidural ropivacaine infusion in children. <i>Br J Anaesth.</i> 2000;85(3):347-353.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26786058">
<a name="26786058"></a>Iliev P, Bhalla T, Tobias JD. A comparison of the hourly output between the Ambu® Smart-Infuser™ Pain Pump and the On-Q Pump® with Select-A-Flow™ Variable Rate Controller with standard and overfill volumes. <i>Paediatr Anaesth</i>. 2016;26(4):425-428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/26786058/pubmed" id="26786058" target="_blank">26786058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). Process for handling elastomeric pain relief balls (ON-Q painbuster and others) requires safety improvements. https://www.ismp.org/resources/process-handling-elastomeric-pain-relief-balls-q-painbuster-and-others-requires-safety. Updated July 16, 2009. Accessed March 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3605712">
<a name="3605712"></a>Ivani G, DeNegri P, Conio A, et al. Comparison of racemic bupivacaine, ropivacaine, and levo-bupivacaine for pediatric caudal anesthesia: effects on postoperative analgesia and motor block. <i>Reg Anesth Pain Med</i>. 2002;27(2):157-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/ 3605712 /pubmed" id=" 3605712 " target="_blank"> 3605712 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10349927">
<a name="10349927"></a>Ivani G, Lampugnani E, De Negri P, Lonnqvist PA, Broadman L. Ropivacaine vs bupivacaine in major surgery in infants. <i>Can J Anaesth</i>. 1999;46(5 Pt 1):467-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/10349927/pubmed" id="10349927" target="_blank">10349927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9813532">
<a name="9813532"></a>Ivani G, Lampugnani E, Torre M, et al. Comparison of ropivacaine with bupivacaine for paediatric caudal block. <i>Br J Anaesth</i>. 1998;81(2):247-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/9813532/pubmed" id="9813532" target="_blank">9813532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18345720">
<a name="18345720"></a>Ivani G, Mossetti V. Regional anesthesia for postoperative pain control in children: focus on continuous central and perineural infusions. <i>Paediatr Drugs</i>. 2008;10(2):107-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/18345720/pubmed" id="18345720" target="_blank">18345720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25693139">
<a name="25693139"></a>Jöhr M. Regional anaesthesia in neonates, infants and children: an educational review. <i>Eur J Anaesthesiol</i>. 2015;32(5):289-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/25693139/pubmed" id="25693139" target="_blank">25693139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11094003">
<a name="11094003"></a>Klein SM, Grant SA, Greengrass RA, et al. Interscalene brachial plexus block with a continuous catheter insertion system and a disposable infusion pump. <i>Anesth Analg.</i> 2000;91(6):1473-1478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/11094003/pubmed" id="11094003" target="_blank">11094003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12753447">
<a name="12753447"></a>Kokinsky E, Nilsson K, Larsson LE. Increased incidence of postoperative nausea and vomiting without additional analgesic effects when a low dose of intravenous fentanyl is combined with a caudal block. <i>Paediatr Anaesth</i>. 2003;13(4):334-338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/12753447/pubmed" id="12753447" target="_blank">12753447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616053">
<a name="15616053"></a>Kokki H, Ylönen P, Laisalmi M, Heikkinen M, Reinikainen M. Isobaric ropivacaine 5 mg/ml for spinal anesthesia in children. <i>Anesth Analg</i>. 2005;100(1):66-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/15616053/pubmed" id="15616053" target="_blank">15616053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589653">
<a name="2589653"></a>Lee A, Fagan D, Lamont M, et al. Disposition kinetics of ropivacaine in humans. <i>Anesth Analg.</i> 1989; 69(6):736-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/2589653/pubmed" id="2589653" target="_blank">2589653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lonnqvist.1">
<a name="Lonnqvist.1"></a>Lonnqvist PA, Westrin P, Larsson BA, et al. Ropivacaine pharmacokinetics after caudal block in 1-8 year old children. <i>Br J Anaesth</i>. 2000;85(4):506-511.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28: peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19282712">
<a name="19282712"></a>Matsota PK, Markantonis SL, Fousteri MZ, et al. Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. <i>Reg Anesth Pain Med</i>. 2009;34(2):126-129. doi:10.1097/AAP.0b013e3181958f39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/19282712/pubmed" id="19282712" target="_blank">19282712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1340763">
<a name="1340763"></a>Miller RD, ed. <i>Miller's Anesthesia</i>. 8th ed. Philadelphia, PA: Elsevier, Inc; 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/1340763/pubmed" id="1340763" target="_blank">1340763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32737881">
<a name="32737881"></a>Mitchell J, Jones W, Winkley E, Kinsella SM. Guideline on anaesthesia and sedation in breastfeeding women 2020: guideline from the Association of Anaesthetists. <i>Anaesthesia</i>. 2020;75(11):1482-1493. doi:10.1111/anae.15179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/32737881/pubmed" id="32737881" target="_blank">32737881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20216035">
<a name="20216035"></a>Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/20216035/pubmed" id="20216035" target="_blank">20216035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Naropin.1">
<a name="Naropin.1"></a>Naropin (ropivacaine hydrochloride) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Naropin.2">
<a name="Naropin.2"></a>Naropin (ropivacaine hydrochloride) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Naropin.3">
<a name="Naropin.3"></a>Naropin (ropivacaine) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31867718">
<a name="31867718"></a>Reschke MM, Monks DT, Varaday SS, Ginosar Y, Palanisamy A, Singh PM. Choice of local anaesthetic for epidural caesarean section: a Bayesian network meta-analysis. <i>Anaesthesia</i>. 2020;75(5):674-682. doi:10.1111/anae.14966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/31867718/pubmed" id="31867718" target="_blank">31867718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24172670">
<a name="24172670"></a>Schloss B, Bhalla T, Klingele K, Phillips D, Prestwich B, Tobias JD. A retrospective review of femoral nerve block for postoperative analgesia after knee surgery in the pediatric population. <i>J Pediatr Orthop</i>. 2014 ;34(4):459-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/24172670/pubmed" id="24172670" target="_blank">24172670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2679230">
<a name="2679230"></a>Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. <i>Anesth Analg.</i> 1989;69(5):563-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/2679230/pubmed" id="2679230" target="_blank">2679230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16392884">
<a name="16392884"></a>Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. <i>Drugs</i>. 2005;65(18):2675-2717. doi:10.2165/00003495-200565180-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/16392884/pubmed" id="16392884" target="_blank">16392884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22587691">
<a name="22587691"></a>Sola C, Raux O, Savath L, Macq C, Capdevila X, Dadure C. Ultrasound guidance characteristics and efficiency of suprazygomatic maxillary nerve blocks in infants: a descriptive prospective study. <i>Paediatr Anaesth</i>. 2012;22(9):841-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/22587691/pubmed" id="22587691" target="_blank">22587691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27920573">
<a name="27920573"></a>Veneziano G, Tripi J, Tumin D, et al. Femoral nerve blockade using various concentrations of local anesthetic for knee arthroscopy in the pediatric population. <i>J Pain Res</i>. 2016;9:1073-1079.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/27920573/pubmed" id="27920573" target="_blank">27920573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26308515">
<a name="26308515"></a>Visoiu M. Paediatric regional anaesthesia: a current perspective. <i>Curr Opin Anaesthesiol</i>. 2015;28(5):577-582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/26308515/pubmed" id="26308515" target="_blank">26308515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25176318">
<a name="25176318"></a>Visoiu M, Joy LN, Grudziak JS, Chelly JE. The effectiveness of ambulatory continuous peripheral nerve blocks for postoperative pain management in children and adolescents. <i>Paediatr Anaesth</i>. 2014;24(11):1141-1148. doi:10.1111/pan.12518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/25176318/pubmed" id="25176318" target="_blank">25176318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22798528">
<a name="22798528"></a>Walker SM, Yaksh TL. Neuraxial analgesia in neonates and infants: a review of clinical and preclinical strategies for the development of safety and efficacy data. <i>Anesth Analg</i>. 2012;115(3):638-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropivacaine-pediatric-drug-information/abstract-text/22798528/pubmed" id="22798528" target="_blank">22798528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wulf.1">
<a name="Wulf.1"></a>Wulf H, Peters C, and Behnke H. The pharmacokinetics of caudal ropivacaine 0.2% in children. A study of infants aged less than 1 year and toddlers aged 1-5 years undergoing inguinal hernia repair. <i>Anaesthesia.</i> 2000;55(8):757-760.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12775 Version 417.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
